ORGANOGENESIS HOLDINGS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.49 USD | 0.00% |
|
+5.96% | -39.12% |
| May. 02 | Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis | CI |
| Feb. 29 | Transcript : Organogenesis Holdings Inc., Q4 2023 Earnings Call, Feb 29, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 499 | 961.6 | 1,189 | 352.2 | 537.1 | 330.1 | - | - |
| Enterprise Value (EV) 1 | 539.4 | 950.5 | 1,148 | 352.2 | 499.5 | 314.8 | 315.4 | 311.3 |
| P/E ratio | -10.9 x | 47.1 x | 13 x | 22.4 x | 102 x | -187 x | 26.2 x | 18.7 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 1.91 x | 2.84 x | 2.54 x | 0.78 x | 1.24 x | 0.73 x | 0.67 x | 0.63 x |
| EV / Revenue | 2.07 x | 2.81 x | 2.45 x | 0.78 x | 1.15 x | 0.69 x | 0.64 x | 0.59 x |
| EV / EBITDA | -29.7 x | 25.8 x | 12.9 x | 7.15 x | 11.7 x | 16.7 x | 9.67 x | 6.85 x |
| EV / FCF | -13,652,303 x | -66,267,174 x | 37,335,547 x | - | - | - | - | - |
| FCF Yield | -0% | -0% | 0% | - | - | - | - | - |
| Price to Book | 9.08 x | 6.58 x | 3.92 x | - | 1.93 x | 2.33 x | 2.24 x | 2.17 x |
| Nbr of stocks (in thousands) | 103,742 | 127,703 | 128,644 | 130,915 | 131,313 | 132,572 | - | - |
| Reference price 2 | 4.810 | 7.530 | 9.240 | 2.690 | 4.090 | 2.490 | 2.490 | 2.490 |
| Announcement Date | 3/9/20 | 3/16/21 | 3/1/22 | 3/1/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 261 | 338.3 | 468.1 | 450.9 | 433.1 | 454.8 | 490.3 | 523.9 |
| EBITDA 1 | -18.16 | 36.88 | 89.14 | 49.27 | 42.62 | 18.84 | 32.63 | 45.44 |
| EBIT 1 | -29.46 | 27.42 | 72.92 | 22.3 | 12.52 | -0.7128 | 18.46 | 34.8 |
| Operating Margin | -11.29% | 8.1% | 15.58% | 4.95% | 2.89% | -0.16% | 3.76% | 6.64% |
| Earnings before Tax (EBT) 1 | -40.3 | 18.48 | 63.79 | 20.28 | 10.39 | -2.946 | 16.09 | 32.76 |
| Net income 1 | -41.1 | 17.95 | 94.9 | 15.53 | 4.945 | -2.035 | 8.391 | 18 |
| Net margin | -15.75% | 5.31% | 20.28% | 3.44% | 1.14% | -0.45% | 1.71% | 3.44% |
| EPS 2 | -0.4400 | 0.1600 | 0.7100 | 0.1200 | 0.0400 | -0.0133 | 0.0950 | 0.1333 |
| Free Cash Flow | -39.51 | -14.34 | 30.76 | - | - | - | - | - |
| FCF margin | -15.14% | -4.24% | 6.57% | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | 34.5% | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | 32.41% | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/9/20 | 3/16/21 | 3/1/22 | 3/1/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 113.8 | 128.6 | 98.12 | 121.4 | 116.9 | 115.5 | 107.6 | 117.3 | 108.5 | 99.65 | 101 | 114.2 | 115.9 | 122.4 | 109.9 |
| EBITDA 1 | 21.65 | 26.35 | 5.004 | 18.6 | 11.6 | 14.06 | 3.768 | 15.4 | 15.97 | 7.473 | -0.1 | 5 | 11.2 | 9.6 | 8.6 |
| EBIT 1 | 16.26 | 20.45 | 0.872 | 11.94 | 1.779 | 8.718 | -4.001 | 9.745 | 8.05 | -1.269 | -5.3 | 0.7 | 1.9 | 2.15 | 1.6 |
| Operating Margin | 14.3% | 15.91% | 0.89% | 9.83% | 1.52% | 7.55% | -3.72% | 8.31% | 7.42% | -1.27% | -5.24% | 0.61% | 1.64% | 1.76% | 1.46% |
| Earnings before Tax (EBT) 1 | 12.88 | 19.59 | 0.132 | 11.18 | 1.212 | 8.754 | -4.627 | 9.179 | 7.637 | -1.796 | -5.8 | 0.2 | 1.4 | 1.65 | 1.1 |
| Net income 1 | 12.58 | 51.7 | 0.087 | 8.744 | 0.215 | 7.486 | -2.969 | 5.316 | 3.167 | -0.568 | -3.6 | -0.2 | 1.2 | 1 | 0.8 |
| Net margin | 11.06% | 40.21% | 0.09% | 7.2% | 0.18% | 6.48% | -2.76% | 4.53% | 2.92% | -0.57% | -3.56% | -0.18% | 1.04% | 0.82% | 0.73% |
| EPS 2 | 0.0900 | 0.3900 | - | 0.0700 | - | 0.0600 | -0.0200 | 0.0400 | 0.0200 | - | -0.0267 | - | 0.0100 | 0.005000 | 0.0100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/21 | 3/1/22 | 5/10/22 | 8/9/22 | 11/9/22 | 3/1/23 | 5/10/23 | 8/9/23 | 11/9/23 | 2/29/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 40.4 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 11.1 | 40.3 | - | 37.6 | 15.3 | 14.7 | 18.8 |
| Leverage (Debt/EBITDA) | -2.226 x | - | - | - | - | - | - | - |
| Free Cash Flow | -39.5 | -14.3 | 30.8 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | -80.1% | 17.8% | 49.4% | - | 1.82% | -0.99% | -0.08% | 1.19% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 0.5300 | 1.140 | 2.350 | - | 2.120 | 1.070 | 1.110 | 1.150 |
| Cash Flow per Share | - | 0.0600 | 0.4600 | - | - | - | - | - |
| Capex 1 | 5.98 | 21.1 | 31.2 | - | 24.4 | 27.2 | 29.3 | 31.3 |
| Capex / Sales | 2.29% | 6.25% | 6.67% | - | 5.62% | 5.98% | 5.98% | 5.97% |
| Announcement Date | 3/9/20 | 3/16/21 | 3/1/22 | 3/1/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.49
USD
Average target price
4.833
USD
Spread / Average Target
+94.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -39.12% | 330M | |
| +25.69% | 47.9B | |
| +46.90% | 41.42B | |
| -3.46% | 40.7B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- ORGO Stock
- Financials Organogenesis Holdings Inc.
